Difference between revisions of "PARP inhibitors"
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
==See also== | ==See also== | ||
*[[Hereditary breast cancer]]. | *[[Hereditary breast cancer]]. | ||
*[[Ovarian | *[[Ovarian tumours]]. | ||
==References== | ==References== | ||
Revision as of 18:26, 10 June 2024
PARP inhibitors are a class of cancer drugs.
PARP is an abbreviation for poly-ADP ribose polymerase.
Use
- Prostate cancer.
- Breast cancer.
- Ovarian cancer.
Drugs
- Olaparib (Lynparza).[1]
- Rucaparib (Rubraca).
- Niraparib (Zejula).
See also
References
- ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.